Bluebird Pinched in Europe; Implications for California Genetic Research
Curative Treatments and the Drive for Profit
Some bad news about a $1.8 million gene therapy echoed across the Atlantic Ocean this week and carries implications for California’s state stem cell agency, which also is engaged in developing so-called “one-and-done” therapies.
The matter involves bluebird bio of Cambridge, Mass., and its proposed Zynteglo therapy for the rare blood disord…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.